Samsung Biologics Issues Its First Annual Sustainability Report
* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...
Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections
* Samsung Biologics' Live Virtual Tour (LVT) used in one of the earliest FDA full virtual assessments * Recently hosted EMA for 6 PAIs simultaneously using LVT INCHEON, South Korea ,June 23, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (C...
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment...
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
* Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022 * The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish ...
Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management
* Expanding upon its existing ISO22301 certification, Samsung Biologics is now fully certified with Business Continuity Management System for Security and Resilience across all business areas * Samsung Biologics adds ISO50001, ISO45001, ISO14001 for Energy Management, Occupational Health and ...
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine
CAMBRIDGE, Mass. and INCHEON, South Korea, May 22, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract develop...
Samsung Biologics Reports First Quarter 2021 Financial Results
* Q1'21 revenue of KRW 260.8 billion increased 26% compared to Q1'20. * Q1'21 operating profit of KRW 74.3 billion increased 19% compared to Q1'20. * Q1'21 operating margin held steady at 28%. * All manufacturing facilities remain fully operational, without any disruptions caused by the COV...
Samsung Biologics Celebrates Its 10th Anniversary with Its Mission, "Driven. For Life."
INCHEON, South Korea, April 21, 2021 /PRNewswire/ -- Samsung Biologics, the
world's leading contract development and manufacturing organization, celebrated
the 10th anniversary of its founding today at its global headquarters in
Songdo, Incheon via a virtual ceremony.
Samsung Biologics Unveils Strong Performance and Future Plans at its 10th Annual General Meeting of Shareholders
INCHEON, South Korea, March 18, 2021 /PRNewswire/ -- Samsung Biologics (KRX:
207940.KS) announced a strong year in 2020 as it reported1 trillion won in
target sales within just a decade at its 10th Annual General Meeting (AGM) on
March 19th Korea time.
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO serv...
Samsung Biologics Reports 66% Increase in 2020 Revenue Achieving "1 Trillion Won" Target Sales
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excelle...
Samsung Biologics Shares 'Vision' for Next Decade at the 39th Annual JP Morgan Healthcare Conference
INCHEON, South Korea, Jan. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS) set forth its dynamic growth plan for the next decade at the 2021 Annual JP Morgan Healthcare Conference.John Rim, newly appointed President and CEO, unveiled a multidimensional business plan for the company to furt...
Samsung Biologics Names John Rim as President and CEO
INCHEON, South Korea, Dec. 16, 2020 /PRNewswire/ -- Samsung Biologics (KRX:
207940.KS) announcedJohn Rim as its President and CEO. The appointment was made
effective immediately and formalized via the company's board of directors
meeting today.
Samsung Biologics drives digital transformation with Plant 4 Virtual Showroom launch
INCHEON, South Korea, Dec. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced the launch of a virtual showroom to provide key features and real-time construction updates of its recently announced Plant 4. The digital showcase also highlights various specs and services that the S...
Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility
INCHEON, South Korea, Nov. 18, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) officially began construction of its Plant 4 in Incheon,South Korea. Dubbed the "Super Plant," the new, multi-story 238,000-square-meter construction will be the world's largest biopharmaceutical manufacturing ...
Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments
INDIANAPOLIS and INCHEON, South Korea, Nov. 17, 2020 /PRNewswire/ -- Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making ...
Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation
INCHEON, South Korea, Oct. 4, 2020 /PRNewswire/ -- Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality (VR) technology to connect with clients around the world. The company's experiential platform won the Best Digi...
Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development
INCHEON, South Korea and SUZHOU, China, Nov. 1, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma ...
Samsung Biologics expands global footprint with opening of new San Francisco CDO R&D Center
INCHEON, South Korea and SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- At a virtual ceremony today, Samsung Biologics (KRX: 207940.KS) announced the grand opening of its first US CDO R&D Center inSan Francisco, bringing its contract development services closer to global clients. As the "Next Door ...
Samsung Biologics' strategic business operations continue to support strong third quarter earnings
INCHEON, South Korea, Oct. 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) maintained steady financial results for its fiscal 2020 third quarter endingSeptember 30, demonstrating confident execution of its ongoing business operations. The Company recorded strong revenues of KRW 274.6...
